CLOs on the Move

Pathology, Inc.

www.pathologyinc.com

 
Pathology Inc. is a 30 man pathology group headquartered in suburban Los Angeles, California offering multi-specialty pathology services for primary care and specialty physicians. The group also practices at 12 area hospitals.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Found

Found is a modern weight care platform pioneering integrated support through personalized coaching, online community, and if indicated, prescription medication. We believe that weight care is complex and goes beyond having the willpower to eat less and move more. We believe in the power of biology, genetics, sleep, stress, mental health and daily habits and we work with each factor to achieve long-lasting results. Our goals are to address the long-term risks associated with ineffective weight management, to reimagine the narrow and outdated cultural narrative around weight, and to empower our community with tools that will help them find self-acceptance and add years to their lives. We believe it`s not just what you`ve lost, it`s what you`ve Found.

Clarassance

Clarassance is a Rockville, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mahaska Health Partnership

Mahaska Health Partnership is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Oskaloosa, IA. To find more information about Mahaska Health Partnership, please visit www.mahaskahealth.org

Apara Autism Center

Apara Autism Centers provides ABA therapy services in Texas to empower autistic individuals with customized support and resources for better life quality.

Alector

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel therapeutics for Alzheimer`s disease, other forms of dementia, and mechanistically related neurodegenerative disorders. Alector`s strategy is to efficiently generate and validate antibody drugs with unique functional properties that engage key disease-altering targets. This approach is enabled by a strategic alliance with Adimab, the industry leader in discovery and optimization of antibody therapeutics. Alector is currently developing leads for 4 major targets and anticipates taking 2 of these through pre-clinical development and IND enabling studies within 24 months. Alector has incorporated a highly integrated and lean biotechnology structure with extensive outsourcing that supports core scientific and management teams.